Gouji Toyokawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gouji Toyokawa has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Takaki Akamine
31 shared publicationsYoshihiko Maehara
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
30 shared publicationsNaoki Haratake
Department of Thoracic Oncology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan
27 shared publicationsYuka Kozuma
Department of Thoracic Surgery, Clinical Research Institute National Hospital Organization, Kyushu Medical Center Fukuoka Japan
27 shared publicationsShinkichi Takamori
Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
25 shared publicationsTaichi Matsubara
25 shared publications
Latest Publications
- 5 October 2026
- Published by S. Karger AG in Respiration
Secondary pleuroparenchymal fibroelastosis shows worse pre-transplant lung function but comparable post-transplant outcomes to idiopathic pleuroparenchymal fibroelastosis
Introduction: Pleuroparenchymal fibroelastosis (PPFE) can be idiopathic (iPPFE) or secondary. Although lung transplantation has been established for advanced PPFE, the clinical characteristics and transplantation outcomes of secondary PPFE remain poorly defined. In this study, we evaluated the parameters of secondary PPFE and iPPFE. Methods: We retrospectively evaluated patients with PPFE who underwent lung transplantation at our institution. The clinical characteristics, transplant outcomes, and longitudinal changes in body mass index (BMI), percent predicted forced vital capacity (%FVC), and the anteroposterior-to-transverse diameter (APDT/TDT) ratio, an indicator of flat chest, were analyzed using linear mixed-effects models. Results: Forty-one patients were included (26 with iPPFE and 15 with secondary PPFE). The underlying cause of secondary PPFE included post-hematopoietic stem cell transplantation in eight patients (53.3%). At baseline, the %FVC (p = 0.017) and APDT/TDT (p = 0.018) were significantly lower in the secondary PPFE group, whereas the BMI did not differ significantly between groups (p = 0.239). Improvements in %FVC tended to be smaller in secondary PPFE at 1 year (estimate −9.61; p = 0.070) and 2 years (estimate −10.37; p = 0.067) after transplantation. Longitudinal analysis demonstrated a significant increase in APDT/TDT over time in both groups, whereas the BMI remained stable with no significant group–time interaction. The 5-year overall survival rates were 71.3% and 71.1% in the iPPFE and secondary PPFE groups, respectively, with no significant differences in overall survival (p = 0.624). The 5-year chronic lung allograft dysfunction-free survival rates were 63.7% and 53.9%, respectively, with no significant intergroup difference (p = 0.487). In a Cox proportional-hazards model, the hazard ratio for overall survival in the secondary PPFE group compared with the iPPFE group was 1.40 (95% CI 0.36–5.41; p = 0.625), and for CLAD-free survival was 1.53 (95% CI 0.46–5.06; p = 0.490). Conclusion: Despite severe preoperative restrictive dysfunction and thoracic deformity, patients with secondary PPFE demonstrated post-transplant functional recovery and long-term transplantation outcomes that did not differ significantly from those with iPPFE, although this comparison was limited by the small number of patients with secondary PPFE and should be interpreted with caution.
- 5 October 2026
- Published by S. Karger AG in Respiration
Secondary pleuroparenchymal fibroelastosis shows worse pre-transplant lung function but comparable post-transplant outcomes to idiopathic pleuroparenchymal fibroelastosis
Introduction: Pleuroparenchymal fibroelastosis (PPFE) can be idiopathic (iPPFE) or secondary. Although lung transplantation has been established for advanced PPFE, the clinical characteristics and transplantation outcomes of secondary PPFE remain poorly defined. In this study, we evaluated the parameters of secondary PPFE and iPPFE. Methods: We retrospectively evaluated patients with PPFE who underwent lung transplantation at our institution. The clinical characteristics, transplant outcomes, and longitudinal changes in body mass index (BMI), percent predicted forced vital capacity (%FVC), and the anteroposterior-to-transverse diameter (APDT/TDT) ratio, an indicator of flat chest, were analyzed using linear mixed-effects models. Results: Forty-one patients were included (26 with iPPFE and 15 with secondary PPFE). The underlying cause of secondary PPFE included post-hematopoietic stem cell transplantation in eight patients (53.3%). At baseline, the %FVC (p = 0.017) and APDT/TDT (p = 0.018) were significantly lower in the secondary PPFE group, whereas the BMI did not differ significantly between groups (p = 0.239). Improvements in %FVC tended to be smaller in secondary PPFE at 1 year (estimate −9.61; p = 0.070) and 2 years (estimate −10.37; p = 0.067) after transplantation. Longitudinal analysis demonstrated a significant increase in APDT/TDT over time in both groups, whereas the BMI remained stable with no significant group–time interaction. The 5-year overall survival rates were 71.3% and 71.1% in the iPPFE and secondary PPFE groups, respectively, with no significant differences in overall survival (p = 0.624). The 5-year chronic lung allograft dysfunction-free survival rates were 63.7% and 53.9%, respectively, with no significant intergroup difference (p = 0.487). In a Cox proportional-hazards model, the hazard ratio for overall survival in the secondary PPFE group compared with the iPPFE group was 1.40 (95% CI 0.36–5.41; p = 0.625), and for CLAD-free survival was 1.53 (95% CI 0.46–5.06; p = 0.490). Conclusion: Despite severe preoperative restrictive dysfunction and thoracic deformity, patients with secondary PPFE demonstrated post-transplant functional recovery and long-term transplantation outcomes that did not differ significantly from those with iPPFE, although this comparison was limited by the small number of patients with secondary PPFE and should be interpreted with caution.
- Open Access
- 2 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (8)
Extended Use of Central Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Pulmonary Arterial Hypertension
Objectives: Lung transplantation (LTx) for patients with pulmonary arterial hypertension (PAH) is associated with high postoperative morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) supports patients’ haemodynamics during and after LTx. However, the optimal ECMO strategy, especially for patients with PAH, is debated. Here, we report our unique strategy for patients with PAH, using postoperative central veno-arterial (VA)-ECMO combined with delayed chest closure. Methods: This was a retrospective single-centre study of consecutive bilateral lung transplantations for adult patients with PAH performed between 2021 and 2024. Patients’ characteristics, perioperative ECMO strategy, and postoperative outcomes were reviewed. Results: During the study period, 20 PAH patients (idiopathic or hereditary PAH [n = 17], PAH secondary to collagen disease [n = 1], pulmonary veno-occlusive disease [n = 1], and Eisenmenger syndrome [n = 1]) underwent cadaveric LTx. Intraoperative support comprised either central VA-ECMO (n = 17) or cardiopulmonary bypass (n = 3). In 17 patients, central VA-ECMO was maintained postoperatively with temporary skin closure. The reason for postoperative central VA-ECMO was anticipated post-LTx heart failure due to PAH and suboptimal cardiac function. The median duration of ECMO support was 4 days (interquartile range: 2-4). There were 9 (45.0%) haemothorax evacuations while patients were on postoperative central VA-ECMO. No patients experienced haemodynamic collapse after LTx. All patients survived during the observation period, resulting in a 100% survival rate at both 90 days and 1 year (95% confidence interval: 83.2%-100%). Conclusions: Extended postoperative central VA-ECMO and delayed chest closure were feasible for patients with PAH who underwent LTx. Meticulous haemostasis is mandatory, given the high chance of haemothorax evacuation.
- 2 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (8)
Open AccessExtended Use of Central Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Pulmonary Arterial Hypertension
Objectives: Lung transplantation (LTx) for patients with pulmonary arterial hypertension (PAH) is associated with high postoperative morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) supports patients’ haemodynamics during and after LTx. However, the optimal ECMO strategy, especially for patients with PAH, is debated. Here, we report our unique strategy for patients with PAH, using postoperative central veno-arterial (VA)-ECMO combined with delayed chest closure. Methods: This was a retrospective single-centre study of consecutive bilateral lung transplantations for adult patients with PAH performed between 2021 and 2024. Patients’ characteristics, perioperative ECMO strategy, and postoperative outcomes were reviewed. Results: During the study period, 20 PAH patients (idiopathic or hereditary PAH [n = 17], PAH secondary to collagen disease [n = 1], pulmonary veno-occlusive disease [n = 1], and Eisenmenger syndrome [n = 1]) underwent cadaveric LTx. Intraoperative support comprised either central VA-ECMO (n = 17) or cardiopulmonary bypass (n = 3). In 17 patients, central VA-ECMO was maintained postoperatively with temporary skin closure. The reason for postoperative central VA-ECMO was anticipated post-LTx heart failure due to PAH and suboptimal cardiac function. The median duration of ECMO support was 4 days (interquartile range: 2-4). There were 9 (45.0%) haemothorax evacuations while patients were on postoperative central VA-ECMO. No patients experienced haemodynamic collapse after LTx. All patients survived during the observation period, resulting in a 100% survival rate at both 90 days and 1 year (95% confidence interval: 83.2%-100%). Conclusions: Extended postoperative central VA-ECMO and delayed chest closure were feasible for patients with PAH who underwent LTx. Meticulous haemostasis is mandatory, given the high chance of haemothorax evacuation.
- Open Access
- 21 June 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (7) , 1373-1375
Successful Management of a Lung Transplant Patient With an Anaphylactic Reaction to Methylprednisolone Sodium Succinate: A Case Report
- 21 June 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (7) , 1373-1375
Open AccessSuccessful Management of a Lung Transplant Patient With an Anaphylactic Reaction to Methylprednisolone Sodium Succinate: A Case Report
- Open Access
- 31 May 2025
- Published by Elsevier in Transplantation Reports
- Vol. 10 (3)
Voriconazole-induced Periostitis Following Lung Transplantation: Case Series
- 31 May 2025
- Published by Elsevier in Transplantation Reports
- Vol. 10 (3)
Open AccessVoriconazole-induced Periostitis Following Lung Transplantation: Case Series
- Open Access
- 1 January 2025
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 31 (1)
Peribronchial Arteriovenous Malformation with Cowden Syndrome: A Rare Case Report
Cowden syndrome (CS) is a rare hereditary disorder caused by a germline variant of the phosphatase and tensin homolog, associated with multiple hamartomatous lesions occurring in various organs. Additionally, although rare, arteriovenous malformations (AVMs) with CS are found in the skin, brain, and spinal cord; however, peribronchial AVMs have not been previously reported. Herein, we report a rare case of a peribronchial AVM in a 30-year-old man with CS who presented with hemoptysis. Computed tomography (CT) revealed an AVM around the left upper bronchus, which was mainly fed by the left bronchial artery and drained into the left inferior pulmonary vein. Under video-assisted thoracic surgery, ligation of the feeding and draining vessels was performed. The AVM remarkably decreased in size one month after the surgery. This case highlights the need for whole-body contrast-enhanced CT to screen for AVMs and the importance of identifying feeding and draining vessels for optimal treatment methods.
- 1 January 2025
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 31 (1)
Open AccessPeribronchial Arteriovenous Malformation with Cowden Syndrome: A Rare Case Report
Cowden syndrome (CS) is a rare hereditary disorder caused by a germline variant of the phosphatase and tensin homolog, associated with multiple hamartomatous lesions occurring in various organs. Additionally, although rare, arteriovenous malformations (AVMs) with CS are found in the skin, brain, and spinal cord; however, peribronchial AVMs have not been previously reported. Herein, we report a rare case of a peribronchial AVM in a 30-year-old man with CS who presented with hemoptysis. Computed tomography (CT) revealed an AVM around the left upper bronchus, which was mainly fed by the left bronchial artery and drained into the left inferior pulmonary vein. Under video-assisted thoracic surgery, ligation of the feeding and draining vessels was performed. The AVM remarkably decreased in size one month after the surgery. This case highlights the need for whole-body contrast-enhanced CT to screen for AVMs and the importance of identifying feeding and draining vessels for optimal treatment methods.
- Open Access
- 1 February 2024
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 2, 1
Should we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?
Should we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?
- 1 February 2024
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 2, 1
Open AccessShould we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?
Should we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?
- Open Access
- 26 June 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (15) , 2198-2204
Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced or recurrent non‐small cell lung cancer (NSCLC). They cause immune‐related adverse events (irAEs), but the underlying mechanisms and predictors remain to be fully elucidated. In this retrospective study, we investigated the association between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and the occurrence of irAEs.Methods: The study involved 115 patients with NSCLC who started ICI‐only treatment in our hospital between January 2016 and April 2020.Results: Forty‐five patients (39.1%) had irAEs, and pretreatment NLR was significantly lower in the irAEs group than in the non‐irAEs group (2.8 vs. 4.1; p = 0.036). The cutoff value of the NLR was 2.86 (area under curve, 0.62; sensitivity, 0.56; specificity, 0.71), and the incidence rate of irAEs was significantly higher in the NLR < 2.86 group than in the NLR ≥2.86 group (p = 0.004; odds ratio [OR]: 3.12; 95% confidence interval [CI]: 1.43–6.84). The multivariate analysis showed that the NLR was significantly associated with the occurrence of irAEs (p = 0.016; OR: 2.69; 95% CI: 1.21–6.01).Conclusions: Low pretreatment NLR may be a predictive factor for the occurrence of irAEs. By focusing on the potential risk of irAEs in patients with a low pretreatment NLR, irAEs can be appropriately managed from an early period.
- 26 June 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (15) , 2198-2204
Open AccessAssociation between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced or recurrent non‐small cell lung cancer (NSCLC). They cause immune‐related adverse events (irAEs), but the underlying mechanisms and predictors remain to be fully elucidated. In this retrospective study, we investigated the association between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and the occurrence of irAEs.Methods: The study involved 115 patients with NSCLC who started ICI‐only treatment in our hospital between January 2016 and April 2020.Results: Forty‐five patients (39.1%) had irAEs, and pretreatment NLR was significantly lower in the irAEs group than in the non‐irAEs group (2.8 vs. 4.1; p = 0.036). The cutoff value of the NLR was 2.86 (area under curve, 0.62; sensitivity, 0.56; specificity, 0.71), and the incidence rate of irAEs was significantly higher in the NLR < 2.86 group than in the NLR ≥2.86 group (p = 0.004; odds ratio [OR]: 3.12; 95% confidence interval [CI]: 1.43–6.84). The multivariate analysis showed that the NLR was significantly associated with the occurrence of irAEs (p = 0.016; OR: 2.69; 95% CI: 1.21–6.01).Conclusions: Low pretreatment NLR may be a predictive factor for the occurrence of irAEs. By focusing on the potential risk of irAEs in patients with a low pretreatment NLR, irAEs can be appropriately managed from an early period.
- 21 June 2021
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 21 (9) , 975-988
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
Anaplastic lymphoma kinase (ALK) inhibitors are widely known to contribute to the long-term survival of ALK-rearranged non-small cell lung cancer (NSCLC) patients. Based on clinical trial data, tre...
- 21 June 2021
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 21 (9) , 975-988
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
Anaplastic lymphoma kinase (ALK) inhibitors are widely known to contribute to the long-term survival of ALK-rearranged non-small cell lung cancer (NSCLC) patients. Based on clinical trial data, tre...